Collins Timire1,2,3, Mkhokheli Ngwenya4, Joconiah Chirenda5, John Z Metcalfe6, Katharina Kranzer3, Debora Pedrazzoli7,8, Kudakwashe C Takarinda1,2, Peter Nguhiu9, Geshem Madzingaidzo1, Kwenzikweyinkosi Ndlovu1, Tawanda Mapuranga1, Morna Cornell10, Charles Sandy1. 1. AIDS & TB Control Programme, Ministry of Health and Child Care, Harare, Zimbabwe. 2. International Union Against Tuberculosis and Lung Disease, Paris, France. 3. Faculty of Infectious & Tropical Diseases, London School of Hygiene &Tropical Medicine, London, UK. 4. Zimbabwe Country Office, World Health Organization, Harare, Zimbabwe. 5. College of Health Sciences, University of Zimbabwe, Harare, Zimbabwe. 6. Division of Pulmonary and Critical Care Medicine, Zuckerberg San Francisco General Hospital and Trauma Center, University of California, San Francisco, CA, USA. 7. Faculty of Epidemiology & Population Health, London School of Hygiene &Tropical Medicine, London, UK. 8. World Health Organization, Geneva, Switzerland. 9. Health Economics Research Unit, Kenya Medical Research Institute, Wellcome Trust Research Programme, Nairobi, Kenya. 10. Centre for Infectious Disease Epidemiology and Research, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa.
Abstract
OBJECTIVES: To determine the incidence and major drivers of catastrophic costs among TB-affected households in Zimbabwe. METHODS: We conducted a nationally representative health facility-based survey with random cluster sampling among consecutively enrolled drug-susceptible (DS-TB) and drug-resistant TB (DR-TB) patients. Costs incurred and income lost due to TB illness were captured using an interviewer-administered standardised questionnaire. We used multivariable logistic regression to determine the risk factors for experiencing catastrophic costs. RESULTS: A total of 841 patients were enrolled and were weighted to 900 during data analysis. There were 500 (56%) males and 46 (6%) DR-TB patients. Thirty-five (72%) DR-TB patients were HIV co-infected. Overall, 80% (95% CI: 77-82) of TB patients and their households experienced catastrophic costs. The major cost driver pre-TB diagnosis was direct medical costs. Nutritional supplements were the major cost driver post-TB diagnosis, with a median cost of US$360 (IQR: 240-600). Post-TB median diagnosis costs were three times higher among DR-TB (US$1,659 [653-2,787]) than drug DS-TB-affected households (US$537 [204-1,134]). Income loss was five times higher among DR-TB than DS-TB patients. In multivariable analysis, household wealth was the only covariate that remained significantly associated with catastrophic costs: The poorest households had 16 times the odds of incurring catastrophic costs versus the wealthiest households (adjusted odds ratio [aOR: 15.7 95% CI: 7.5-33.1]). CONCLUSION: The majority of TB-affected households, especially those affected by DR-TB, experienced catastrophic costs. Since the major cost drivers fall outside the healthcare system, multi-sectoral approaches to TB control and linking TB patients to social protection may reduce catastrophic costs.
OBJECTIVES: To determine the incidence and major drivers of catastrophic costs among TB-affected households in Zimbabwe. METHODS: We conducted a nationally representative health facility-based survey with random cluster sampling among consecutively enrolled drug-susceptible (DS-TB) and drug-resistant TB (DR-TB) patients. Costs incurred and income lost due to TB illness were captured using an interviewer-administered standardised questionnaire. We used multivariable logistic regression to determine the risk factors for experiencing catastrophic costs. RESULTS: A total of 841 patients were enrolled and were weighted to 900 during data analysis. There were 500 (56%) males and 46 (6%) DR-TB patients. Thirty-five (72%) DR-TB patients were HIV co-infected. Overall, 80% (95% CI: 77-82) of TB patients and their households experienced catastrophic costs. The major cost driver pre-TB diagnosis was direct medical costs. Nutritional supplements were the major cost driver post-TB diagnosis, with a median cost of US$360 (IQR: 240-600). Post-TB median diagnosis costs were three times higher among DR-TB (US$1,659 [653-2,787]) than drug DS-TB-affected households (US$537 [204-1,134]). Income loss was five times higher among DR-TB than DS-TB patients. In multivariable analysis, household wealth was the only covariate that remained significantly associated with catastrophic costs: The poorest households had 16 times the odds of incurring catastrophic costs versus the wealthiest households (adjusted odds ratio [aOR: 15.7 95% CI: 7.5-33.1]). CONCLUSION: The majority of TB-affected households, especially those affected by DR-TB, experienced catastrophic costs. Since the major cost drivers fall outside the healthcare system, multi-sectoral approaches to TB control and linking TB patients to social protection may reduce catastrophic costs.
Authors: N V Nhung; N B Hoa; N T Anh; L T Ngoc Anh; A Siroka; K Lönnroth; I Garcia Baena Journal: Int J Tuberc Lung Dis Date: 2018-09-01 Impact factor: 2.373
Authors: Debora Pedrazzoli; Andrew Siroka; Delia Boccia; Frank Bonsu; Kenneth Nartey; Rein Houben; Josephine Borghi Journal: Trop Med Int Health Date: 2018-06-25 Impact factor: 2.622
Authors: William E Rudgard; Nancy S das Chagas; Regina Gayoso; Mauricio L Barreto; Delia Boccia; Liam Smeeth; Laura C Rodrigues; Knut Lönnroth; Elizabeth Williamson; Ethel L N Maciel Journal: Eur Respir J Date: 2018-03-22 Impact factor: 16.671
Authors: Collins Timire; John Z Metcalfe; Joconiah Chirenda; Jerod N Scholten; Barbara Manyame-Murwira; Mkhokheli Ngwenya; Ronnie Matambo; Kelvin Charambira; Herbert Mutunzi; Nico Kalisvaart; Charles Sandy Journal: Int J Infect Dis Date: 2019-07-27 Impact factor: 12.074
Authors: Tom Wingfield; Marco A Tovar; Doug Huff; Delia Boccia; Rosario Montoya; Eric Ramos; James J Lewis; Robert H Gilman; Carlton A Evans Journal: Eur Respir J Date: 2016-09-22 Impact factor: 16.671